A 42-year-old man with moderate persistent asthma controlled on inhaled fluticasone 100 mcg BD presents with a 2-week history of increased shortness of breath, cough, and wheezing despite compliance with his regular inhaler. He reports using his salbutamol inhaler 4–5 times daily. On examination, he has widespread end-expiratory wheeze, peak flow is 55% of his personal best, and oxygen saturation is 92% on room air. Chest X-ray is clear. What is the most appropriate immediate management?

Explanation

## Clinical Assessment of Acute Asthma Exacerbation This patient presents with **acute asthma exacerbation** superimposed on previously controlled moderate persistent asthma. ### Severity Indicators | Finding | This Patient | Significance | |---------|--------------|-------------| | Peak flow | 55% of personal best | **Moderate-to-severe exacerbation** (50–79% = moderate; <50% = severe) | | SpO₂ | 92% on room air | Mild hypoxemia | | Symptom duration | 2 weeks | Prolonged deterioration | | SABA use | 4–5 times daily | Inadequate control | | Chest X-ray | Clear | No pneumonia/pneumothorax | **Key Point:** Peak flow 55% of personal best falls in the **moderate exacerbation range** (50–79%), not severe (<50%). This patient does NOT require hospital admission but needs urgent step-up in therapy. ## Management Algorithm for Acute Exacerbation ```mermaid flowchart TD A[Acute asthma exacerbation]:::outcome --> B{Peak flow / FEV₁?}:::decision B -->|>80% predicted| C[Mild exacerbation]:::outcome B -->|50-79% predicted| D[Moderate exacerbation]:::outcome B -->|<50% predicted| E[Severe exacerbation]:::outcome C --> F[Oral corticosteroids<br/>+ SABA PRN<br/>Outpatient review 24-48h]:::action D --> G[Oral corticosteroids<br/>+ SABA PRN<br/>+ Step-up ICS or add LABA<br/>Review 1-2 weeks]:::action E --> H[Hospital admission<br/>IV/IM corticosteroids<br/>Continuous nebulized SABA<br/>Oxygen, IV magnesium]:::urgent G --> I[Reassess control<br/>Identify trigger]:::action ``` ### Why Oral Corticosteroids + LABA Addition? **High-Yield:** In moderate exacerbations with inadequate control on ICS monotherapy, the dual approach addresses both acute inflammation and underlying control: 1. **Oral corticosteroids (prednisolone 0.5–1 mg/kg/day for 7–14 days)** - Rapidly suppresses airway inflammation - Reduces relapse risk by ~50% - Standard of care for any exacerbation requiring treatment beyond SABA 2. **Add LABA to existing ICS (ICS + LABA combination)** - Indicates step-up from step 2 (ICS monotherapy) to step 3 - LABA + ICS combination provides superior control vs. ICS alone - Prevents future exacerbations - LABA must ALWAYS be paired with ICS (never monotherapy) **Clinical Pearl:** This patient's exacerbation on ICS monotherapy suggests inadequate baseline control. Adding a LABA (e.g., fluticasone + salmeterol combination inhaler) is the evidence-based step-up strategy per GINA. ### Rationale Against Other Options - **Increasing ICS dose alone** (option A): Insufficient for acute exacerbation; does not address acute inflammation or step-up need. - **IV magnesium + continuous nebulization** (option C): Reserved for severe exacerbations (peak flow <50%) or those with poor response to SABA. This patient is moderate and can be managed as outpatient. - **Switching ICS** (option D): No evidence for benefit; delays appropriate therapy. **Mnemonic:** **OCS + LABA = Step-Up in Exacerbation** — Oral Corticosteroids for acute inflammation; LABA addition for long-term control step-up.